Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Thwin, Maung Maung ^a   Douni, Eleni ^b   Arjunan, Pachiappan ^c   Kollias, George ^b   Kumar, Prem V ^a   Gopalakrishnakone, Ponnampalam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFLAMIN 2; ANTIRHEUMATIC AGENT; CELECOXIB; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE INHIBITOR FROM PYTHON 18; STROMELYSIN; SYNTHETIC PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARESPLADIB; ENZYME INHIBITOR; PEPTIDE; SECRETORY PHOSPHOLIPASE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; FIBROBLAST CULTURE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RNA TRANSCRIPTION; SYNOVIOCYTE; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG ANTAGONISM; FIBROBLAST; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION; HUMANS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; PEPTIDES; PHOSPHOLIPASES A2, SECRETORY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75649106881     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2810     Document Type: Article

References (67)

1. Bongartz TA, Sutton J, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
2. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
3. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003, 62 Suppl 2:ii43-ii47. 14532148, 1766743.
4. Masuda S, Murakami M, Komiyama K, Ishihara M, Ishikawa Y, Ishii T, Kudo I. Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. FEBS J 2005, 272:655-672. 10.1111/j.1742-4658.2004.04489.x, 15670148.
5. Yedgar S, Cohen Y, Shoseyov D. Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 2006, 1761:1373-1382. 16978919.
6. Triggiani M, Granata F, Frattini A, Marone G. Activation of human inflammatory cells by secreted phospholipase A2 (A Review). Biochim Biophys Acta 2006, 1761:1289-1300. 16952481.
7. Granata F, Balestrieri B, Petraroli A, Giannattasio G, Marone G, Triggiani M. Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol 2003, 131:153-163. 10.1159/000071481, 12876405.
8. Thwin MM, Ong WY, Fong CW, Sato K, Kodama K, Farooqui AA, Gopalakrishnakone P. Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum. Exp Brain Res 2003, 150:427-433.
9. Thwin MM, Gopalakrishnakone P, Kini RM, Armugam A, Jeyaseelan K. Recombinant antitoxic and antiinflammatory factor from the nonvenomous snake Python reticulatus: phospholipase A2 inhibition and venom neutralizing potential. Biochemistry 2000, 39:9604-9611. 10.1021/bi000395z, 10924158.
10. Thwin MM, Douni E, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 2004, 6:R282-294. 416452, 15142275, 10.1186/ar1179.
11. Thwin MM, Satyanarayanajois SD, Nagarajarao LM, Sato K, Arjunan P, Ramapatna SL, Kumar PV, Gopalakrishnakone P. Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling. J Med Chem 2007, 50:5938-5950. 10.1021/jm070385x, 17973469.
12. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543. 16146751, 10.2741/1817.
13. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001, 60:iii62-iii67. 1766680, 11890658.
14. Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD. A randomized, double-blinded, placebo-controlled clinical trial of LY333013 a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005, 32:417-423.
15. Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, Schein RM, Macias W, Skerjanec S, Dmitrienko A, Farid N, Forgue ST, Jiang F. Efficacy and safety of LY315920Na/S- a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003, 31:718-728. 12626975, 10.1097/01.CCM.0000053648.42884.89.
16. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031. 453150, 1721867.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
18. Versteeg HH, Nijhuis E, Brink GR, Evertzen M, Pynaert GN, van Deventer SJ, Coffer PJ, Peppelenbosch MP. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 2000, 350:717-722. 1221302, 10970784, 10.1042/0264-6021:3500717.
19. Pachiappan A, Thwin MM, Manikandan J, Gopalakrishnakone P. Glial inflammation and neurodegeneration induced by candoxin, a novel neurotoxin from Bungarus candidus venom: global gene expression analysis using microarray. Toxicon 2005, 46:883-899. 10.1016/j.toxicon.2005.08.017, 16309724.
20. Livak KJ, Schmittge TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
21. Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 2004, 6:R65-R72. 14979939, 400419, 10.1186/ar1028.
22. Inglis JJ, Criado G, Medghalchi M, Andrews M, Sandison A, Feldmann M, Williams RO. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther 2007, 9:R113-120. 2212575, 17967186, 10.1186/ar2319.
23. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788. 50217, 1409699, 10.1073/pnas.89.20.9784.
24. Gebhard HH, Zysk SP, Schmitt-Sody M, Jansson V, Messmer K, Veihelmann A. The effects of celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis. Clin Exp Rheumatol 2005, 23:63-70.
25. Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH. Pharmacology of LY315920/S- [3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl] oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 1999, 288:1117-1124. 10027849.
26. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE. Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem 1998, 41:3568-3571. 10.1021/jm980253r, 9733482.
27. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005, 102:3697-3702. 552783,552783, 15738394, 10.1073/pnas.0500369102.
28. Meyer MC, Rastogi P, Beckett CS, McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 2005, 11:1301-1312. 10.2174/1381612053507521, 15853686.
29. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007, 13:333-346. 10.2174/138161207779313551, 17313364.
30. Nuti E, Tuccinardi T, Rossello A. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 2007, 13:2087-2100. 10.2174/138161207781039706, 17627541.
31. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis:destruction or repair?. Nat Clin Pract Rheumatol 2008, 4:128-135. 10.1038/ncprheum0727, 18253109.
32. Pruzanski W. Phospholipase A2: quo vadis?. J Rheumatol 2005, 32:400-402.
33. Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE, Hartley LW, Jones ND, Mihelich ED, Olkowski JL, Snyder DW, Sommers C, Wery JP. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol 1995, 2:458-465. 7664108, 10.1038/nsb0695-458.
34. Hulkower KI, Wertheimer SJ, Levin W, Coffey JW, Anderson CM, Chen T, DeWitt DL, Crowl RM, Hope WC, Morgan DW. Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2. Arthritis Rheum 1994, 37:653-661. 10.1002/art.1780370508, 8185692.
35. Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol 2000, 165:2790-2797.
36. Lee C, Lee J, Choi YA, Kang SS, Baek SH. cAMP elevating agents suppress secretory phospholipase A(2)-induced matrix metalloproteinase-2 activation. Biochem Biophys Res Commun 2006, 340:1278-1283. 10.1016/j.bbrc.2005.12.136, 16414357.
37. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:409-414. 18187523, 10.1093/rheumatology/kem297.
38. Ravanti L, Heino J, López-Otín C, Kähäri VM. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1999, 274:2446-2455. 10.1074/jbc.274.4.2446, 9891015.
39. Reunanen N, Li SP, Ahonen M, Foschi M, Han J, Kähäri VM. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002, 277:32360-32368. 10.1074/jbc.M204296200, 12060661.
40. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J Biol Chem 2004, 279:39513-39519. 10.1074/jbc.M405844200, 15269222.
41. Brown RD, Jones GM, Laird RE, Hudson P, Long CS. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun 2007, 362:200-205. 2017114, 17706606, 10.1016/j.bbrc.2007.08.003.
42. Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 6 a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004, 63:1453-1459. 15479895, 1754789, 10.1136/ard.2003.013011.
43. Müller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 2007, 9:223-212. 2246247, 18177509, 10.1186/ar2337.
44. Corcoran ML, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein 1996, 49:7-19.
45. Church WB, Inglis AS, Tseng A, Duell R, Lei PW, Bryant KJ, Scott KF. A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition. J Biol Chem 2001, 276:33156-33164. 10.1074/jbc.M101272200, 11427527.
46. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002, 4:157-164. 128926, 12010565, 10.1186/ar401.
47. Kuwata H, Nonaka T, Murakami M, Kudo I. Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway. J Biol Chem 2005, 280:25830-25839. 10.1074/jbc.M500168200, 15878884.
48. Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L, Tschachler E, Wagner EF. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther 2008, 10:201-210. 2374460, 18226189, 10.1186/ar2338.
49. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006, 54:2745-2756. 10.1002/art.22080, 16947383.
50. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008, 67:909-916. 2754165, 17827184, 10.1136/ard.2007.074278.
51. Mounier CM, Ghomashchi F, Lindsay MR, James S, Singer AG, Parton RG, Gelb MH. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha. J Biol Chem 2004, 279:25024-25038. 10.1074/jbc.M313019200, 15007070.
52. Han WK, Sapirstein A, Hung CC, Alessandrini A, Bonventre JV. Cross-talk between cytosolic phospholipase A2 alpha (cPLA2 alpha) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA2 regulates cPLA2 alpha activity that is responsible for arachidonic acid release. J Biol Chem 2003, 278:24153-24163. 10.1074/jbc.M300424200, 12676927.
53. Huwiler A, Staudt G, Kramer RM, Pfeilschifter J. Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. Biochim Biophys Acta 1997, 1348:257-272.
54. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for Industry Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) 1999, FDA, Silver Spring, MD, USA, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
55. Wada Y, Nakajima-Yamada T, Yamada K, Tsuchida J, Yasumoto T, Shimozato T, Aoki K, Kimura T, Ushiyama S. R-13 a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol 2005, 506:285-295. 15627439, 10.1016/j.ejphar.2004.11.013.
56. Patten C, Bush K, Rioja I, Morgan R, Wooley P, Trill J, Life P. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. Arthritis Rheum 2004, 50:3334-3345. 10.1002/art.20507, 15476226.
57. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997, 159:2867-2876.
58. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 2000, 165:1605-1611.
59. Moreno JJ. Antiflammin peptides in the regulation of inflammatory response. Ann N Y Acad Sci 2000, 923:147-153.
60. Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, Ohya K, Aoki K. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum 2007, 56:1164-1174. 10.1002/art.22495, 17393436.
61. Beck S, Lambeau G, Scholz-Pedretti K, Gelb MH, Janssen MJ, Edwards SH, Wilton DC, Pfeilschifter J, Kaszkin M. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2(sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem 2003, 278:29799-29812. 10.1074/jbc.M211763200, 12782627.
62. Pruzanski W, Bogoch E, Katz A, Wloch M, Stefanski E, Grouix B, Sakotic G, Vadas P. Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. J Rheumatol 1995, 22:2114-2119.
63. Leistad L, Feuerherm AJ, Ostensen M, Faxvaag A, Johansen B. Presence of secretory group IIa and V phospholipase A2 and cytosolic group IV alpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis. Clin Chem Lab Med 2004, 42:602-610. 10.1515/CCLM.2004.104, 15259375.
64. Cho TJ, Lehmann W, Edgar C, Sadeghi C, Hou A, Einhorn TA, Gerstenfeld LC. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. Arthritis Rheum 2003, 48:2845-2854. 10.1002/art.11390, 14558090.
65. Zwerina J, Tuerk B, Redlich K, Smolen JS, Schett G. Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2006, 8:R22-32. 1526585, 16507121, 10.1186/ar1872.
66. Tian L, Stefanidakis M, Ning L, Van Lint P, Nyman-Huttunen H, Libert C, Itohara S, Mishina M, Rauvala H, Gahmberg CG. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol 2007, 178:687-700. 2064474, 17682049, 10.1083/jcb.200612097.
67. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci USA 2008, 105:19520-19525. 2614793, 19047646, 10.1073/pnas.0807248105.